MYRIAD
OUR
RESEARCH		  
     
 
   

References

  1. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer’s disease. Lancet. 1997;349:1546-1549. PMID: 9167474
  2. National Institute on Aging. 2000 Progress Report on Alzheimer’s disease. Available at: http://www.alzheimers.org/prog00.htm#clippingenzymes. Accessed April 29, 2006.
  3. Selkoe DJ, Schenk D. Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2003;43:545-584. PMID: 12415125
  4. Personal communication. Professor Konrad Maurer, Head of the Department of Psychiatry and Psychotherapy, Johann Wolfgang Goethe-University of Frankfurt/Main, Frankfurt, Germany. April 2006.
  5. Cummings JL. Alzheimer’s disease. N Engl J Med. 2004;351:56-67. PMID: 15229308
  6. United States Census Bureau. Projected population of the United States, by age and sex: 2000 to 2050. US Census Bureau, Population Division, Population Projections Branch: 2004. Available at: http://www.census.gov/ipc/www/usinterimproj/natprojtab02a.pdf. Accessed April 12, 2006.
  7. United States Census Bureau. Table 1: Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2004 (NC-EST2004-01). Population Division, U.S. Census Bureau. June 9, 2005. Available at: http://www.census.gov/popest/national/asrh/
    NC-EST2004/NC-EST2004-01.xls    . Accessed April 12, 2006.
  8. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004;35(suppl 1):2620-2622. PMID: 15375299
  9. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119-1122. PMID: 12925369
  10. Kirschstein R. Disease-specific estimates of direct and indirect costs of illness and NIH support. Fiscal year 2000 update. National Institutes of Health. Available at: http://ospp.od.nih.gov/ecostudies/COIreportweb.htm. Accessed April 23, 2006.
  11. Koppel R. Alzheimer’s disease: the costs to U.S. businesses in 2002. Alzheimer’s Association, 2002.
  12. Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med. 2001;16:770-778. PMID: 11722692
  13. MetLife Mature Market Institute. The MetLife market survey of nursing home & home care costs. MetLife Mature Market Institute. Westport, CT. September 2005.
  14. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov. 2003;2:646-653. PMID: 12904814
  15. Dunkin JJ, Anderson-Hanley C. Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention. Neurology. 1998;51(suppl 1):S53-S60. PMID: 9674763
  16. Christakis NA, Allison PD. Mortality after the hospitalization of a spouse. N Engl J Med. 2006;354:719-730. PMID: 16481639
  17. Gross J. As parents age, baby boomers and business struggle to cope. The New York Times. nytimes.com. March 25, 2006;sect A:1.
  18. Harris Interactive Inc. I CAN: Investigating Caregivers’ Attitudes and Needs. Survey conducted for the Alzheimer’s Foundation of America. March 2006.
  19. Citron M. Strategies for disease modification in Alzheimer’s disease. Nat Rev Neurosci. 2004;5:677-685. PMID: 15322526
  20. Jannis S. Inside the Brain: An Interactive Tour. Slide 9 image credit: Jannis Productions. Copyright© 2006 Alzheimer’s Association. Available at: http://www.alz.org/brain/overview.asp. Accessed April 23, 2006.
  21. Selkoe DJ. Defining molecular targets to prevent Alzheimer disease. Arch Neurol. 2005;62:192-195. PMID: 15710846
  22. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356. PMID: 12130773
  23. National Institute on Aging. Progress Report on Alzheimer’s Disease 2004-2005. New discoveries, new insights. National Institutes of Health, Publication Number 05-5724; November 2005.
  24. Golde TE. Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest. 2003;111:11-18. PMID: 12511580
  25. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem. 2003;278:30748-30754. PMID: 12777371
  26. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112:440-449. PMID: 12897211
  27. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer’s disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health. 2002;23:213-231. PMID: 11910061
  28. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342. PMID: 9736873
   

Alzheimer's Brochure (pdf)

  
© 2008 Myriad Genetics, Inc.